CTOs on the Move

Octamer

www.octamer.com

 
Octamer is a Belvedere Tiburon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.octamer.com
  • 392 Cecilia Way
    Belvedere Tiburon, CA USA 94920
  • Phone: 415.381.1602

Executives

Name Title Contact Details

Similar Companies

Enalare Therapeutics

Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.

NS Pharma

NS Pharma is a biopharmaceutical company focused on researching and developing treatments for rare diseases, with a current focus on optimizing exon skipping therapy for Duchenne muscular dystrophy.

KCR

KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).